The effect of using oxytocin in individuals with body dysmorphic disorder (BDD)

Swinburne University of Technology0 sites46 target enrollmentMarch 16, 2022

Overview

No summary available.

Registry

who.int

Start Date

March 16, 2022

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Sex

All

Sponsor

•Participants will i) be aged between 18\-55 years (inclusive); ii) have a primary diagnosis of BDD according to the Diagnostic and Statistical Manual\-5 (DSM\-5\); iii) score of 24 or higher on the BDD\-YBOCS (to ensure at least moderate symptom severity); iv) have an estimated IQ of 70 or higher as assessed using the Test of Premorbid Functioning (TOPF) to ensure no intellectual disability and study instructions are understood; v) have been stabilised on psychotropic medications, if prescribed, for 8weeks or longer; vi) be right\-handed (to meet eligibility for MRI); vii) utilising effective contraception if female and of childbearing age; and viii) have capacity to consent to the study. Further, BDD patients frequently report co\-morbid depression, social anxiety and psychoses. To ensure our sample is representative, patients with co\-morbidities will be included.

•Participants will be excluded if i) substance use disorder is present; ii) they are unable to meaningfully converse in, or read, English; iii) they have metal implants or a history of claustrophobia (to meet eligibility for an MRI); iv) neuroendocrine dysfunction or steroid use is present; vi) they have been diagnosed with any known neurological disorder; v) they are currently pregnant or breastfeeding, vi) have an ongoing sinus condition and vii) history of hypersensitivity to oxytocin.